<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alexander, Walter</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Powell, Bayard L.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Consolidation with Arsenic Trioxide Significantly Improves Event-free Survival and Overall Survival among Patients with Newly Diagnosed Acute Promyelocytic Leukemia</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2007-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">12-12</style></pages><abstract><style  face="normal" font="default" size="100%">Arsenic trioxide is an effective and indicated agent for relapsed acute promyelocytic leukemia (APL). A study now demonstrates that arsenic trioxide has clinical benefit for patients with newly diagnosed APL. This article reports findings from the study in which arsenic trioxide was given as consolidation therapy to patients with APL who had complete remission following standard induction therapy.</style></abstract><number><style face="normal" font="default" size="100%">3</style></number><volume><style face="normal" font="default" size="100%">7</style></volume></record></records></xml>